{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:50:55Z","timestamp":1788364255576,"version":"build-2803163510"},"reference-count":12,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007185","name":"University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.xkme.2025.100998","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T02:18:45Z","timestamp":1742437125000},"page":"100998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Acute Kidney Injury Secondary to Pegylated Liposomal Doxorubicin-Associated Renal-limited Thrombotic Microangiopathy"],"prefix":"10.1016","volume":"7","author":[{"given":"Tarek S.","family":"Karam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinalini","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Zuckerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.xkme.2025.100998_bib1","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.xkme.2025.100998_bib2","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3390\/ph16060802","article-title":"Recent advances in doxorubicin formulation to enhance pharmacokinetics and tumor targeting","volume":"16","author":"Lee","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"10.1016\/j.xkme.2025.100998_bib3","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.xkme.2025.100998_bib4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1517\/14740330902942299","article-title":"Thrombotic microangiopathy associated with gemcitabine: rare but real","volume":"8","author":"Saif","year":"2009","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"10.1016\/j.xkme.2025.100998_bib5","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1053\/j.ajkd.2010.06.006","article-title":"The role of endothelial cell injury in thrombotic microangiopathy","volume":"56","author":"Goldberg","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1016\/j.xkme.2025.100998_bib6","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0959-8049(01)00050-8","article-title":"Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL\/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group","volume":"37","author":"Judson","year":"2001","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.xkme.2025.100998_bib7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/ki.2012.484","article-title":"Glomerular diseases seen with cancer and\u00a0chemotherapy: a narrative review","volume":"84","author":"Jhaveri","year":"2013","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.xkme.2025.100998_bib8","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000188623","article-title":"Nephrotic syndrome developed in a patient with acute promyelocytic leukemia treated with daunomycin","volume":"70","author":"Morino","year":"1995","journal-title":"Nephron"},{"issue":"12","key":"10.1016\/j.xkme.2025.100998_bib9","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1634\/theoncologist.2011-0422","article-title":"Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?","volume":"17","author":"Kwa","year":"2012","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.xkme.2025.100998_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100461","article-title":"Pegylated liposomal doxorubicin and kidney-limited thrombotic microangiopathy in a kidney transplant recipient: a case report","volume":"4","author":"Rodriguez-Ramirez","year":"2022","journal-title":"Kidney Med"},{"issue":"4","key":"10.1016\/j.xkme.2025.100998_bib11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1053\/j.ajkd.2023.08.014","article-title":"Pegylated liposomal doxorubicin causes kidney-limited thrombotic microangiopathy","volume":"83","author":"Glezerman","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1016\/j.xkme.2025.100998_bib12","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1053\/j.ajkd.2012.08.048","article-title":"Collapsing glomerulopathy following anthracycline therapy","volume":"61","author":"Mohamed","year":"2013","journal-title":"Am J Kidney Dis"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525000342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525000342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T10:00:59Z","timestamp":1746612059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059525000342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2590059525000342"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2025.100998","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Kidney Injury Secondary to Pegylated Liposomal Doxorubicin-Associated Renal-limited Thrombotic Microangiopathy","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2025.100998","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"100998"}}